A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Dostarlimab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer
- Focus Registrational; Therapeutic Use
- Acronyms AZUR-2
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 20 Jan 2024 Trial deisgn presented at the 2024 Gastrointestinal Cancers Symposium
- 02 Jan 2024 Planned End Date changed from 31 Jan 2031 to 15 Dec 2028.
- 02 Jan 2024 Planned primary completion date changed from 23 Jan 2029 to 15 Dec 2028.